Serum metabolomics indicate altered cellular energy metabolism in children with cystic fibrosis
- 12 July 2013
- journal article
- research article
- Published by Wiley in Pediatric Pulmonology
- Vol. 49 (5) , 463-472
Abstract
Background Cystic fibrosis (CF) is a multi-system disease affecting multiple organs and cells besides the respiratory system. Metabolomic profiling allows simultaneous detection of biochemicals originating from cells, organs, or exogenous origin that may be valuable for monitoring of disease severity or in diagnosis. Aim We hypothesized that metabolomics using serum from children would differentiate CF from non-CF lung disease subjects and would provide insight into metabolism in CF. Methods Serum collected from children with CF (n = 31) and 31 age and gender matched children with other lung diseases was used for metabolomic profiling by gas- and liquid-chromatography. Relative concentration of metabolites was compared between the groups using partial least square discriminant analyses (PLS-DA) and linear modeling. Results A clear separation of the two groups was seen in PLS-DA. Linear model found that among the 459 detected metabolites 92 differed between CF and non-CF. These included known biochemicals in lipid metabolism, oxidants, and markers consistent with abnormalities in bile acid processing. Bacterial metabolites were identified and differed between the groups indicating intestinal dysbiosis in CF. As a novel finding several pathways were markedly different in CF, which jointly point towards decreased activity in the β-oxidation of fatty acids. These pathways include low ketone bodies, low medium chain carnitines, elevated di-carboxylic acids and decreased 2-hydroxybutyrate from amino acid metabolism in CF compared to non-CF. Conclusion Serum metabolomics discriminated CF from non-CF and show altered cellular energy metabolism in CF potentially reflecting mitochondrial dysfunction. Future studies are indicated to examine their relation to the underlying CF defect and their use as biomarkers for disease severity or for cystic fibrosis transmembrane regulator (CFTR) function in an era of CFTR modifying drugs. Pediatr Pulmonol. 2014; 49:463–472.Keywords
Funding Information
- Cystic Fibrosis Foundation Therapeutics
This publication has 48 references indexed in Scilit:
- The Emerging Field of Quantitative Blood Metabolomics for Biomarker Discovery in Critical IllnessesAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Plasma lipidomics reveals potential prognostic signatures within a cohort of cystic fibrosis patientsJournal of Lipid Research, 2011
- Metabolomic Profiling Reveals Biochemical Pathways and Biomarkers Associated with Pathogenesis in Cystic Fibrosis CellsJournal of Biological Chemistry, 2010
- α-Hydroxybutyrate Is an Early Biomarker of Insulin Resistance and Glucose Intolerance in a Nondiabetic PopulationPLOS ONE, 2010
- Metabolomic profiling can predict which humans will develop liver dysfunction when deprived of dietary cholineThe FASEB Journal, 2010
- Individual variation in macronutrient regulation measured by proton magnetic resonance spectroscopy of human plasmaAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2009
- Dysfunction of Nrf-2 in CF Epithelia Leads to Excess Intracellular H2O2 and Inflammatory Cytokine ProductionPLOS ONE, 2008
- Mitochondrial Oxidative Stress in the Lungs of Cystic Fibrosis Transmembrane Conductance Regulator Protein Mutant MiceAmerican Journal of Respiratory Cell and Molecular Biology, 2006
- Normal energy expenditure in the infant with presymptomatic cystic fibrosisThe Journal of Pediatrics, 1995
- Energy expenditure of patients with cystic fibrosisThe Journal of Pediatrics, 1987